1. Home
  2. AVB vs NTRA Comparison

AVB vs NTRA Comparison

Compare AVB & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AVB

AvalonBay Communities Inc.

HOLD

Current Price

$182.26

Market Cap

25.5B

Sector

Real Estate

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$231.25

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVB
NTRA
Founded
1978
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.5B
27.0B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
AVB
NTRA
Price
$182.26
$231.25
Analyst Decision
Buy
Strong Buy
Analyst Count
15
15
Target Price
$205.70
$249.53
AVG Volume (30 Days)
994.6K
1.1M
Earning Date
02-04-2026
02-26-2026
Dividend Yield
3.84%
N/A
EPS Growth
12.03
N/A
EPS
8.20
N/A
Revenue
$3,065,608,000.00
$2,116,676,000.00
Revenue This Year
$3.26
$33.18
Revenue Next Year
$3.95
$16.81
P/E Ratio
$22.25
N/A
Revenue Growth
6.50
38.17
52 Week Low
$166.73
$125.38
52 Week High
$230.21
$256.36

Technical Indicators

Market Signals
Indicator
AVB
NTRA
Relative Strength Index (RSI) 53.44 47.41
Support Level $175.00 $226.12
Resistance Level $182.54 $243.03
Average True Range (ATR) 3.85 9.12
MACD -0.09 -0.98
Stochastic Oscillator 61.60 17.70

Price Performance

Historical Comparison
AVB
NTRA

About AVB AvalonBay Communities Inc.

AvalonBay Communities owns a portfolio of 295 apartment communities with almost 90,000 units and is developing 20 additional properties with approximately 7,300 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: